SCHEMBL5870948

SCHEMBL5870948

CCC(=O)N(CC1CCCN(C(=O)OC(C)(C)C)C1)c1cccnc1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 1/20 0.46
GPR119 Q8TDV5 4/20 0.46
BACE1 P56817 2/20 0.42
ACKR3 P25106 1/20 0.42
CTSD P07339 1/20 0.42
FNTA P49354 1/20 0.41
FNTB P49356 1/20 0.41
KDM1A O60341 1/20 0.41
GLS O94925 2/20 0.40
FEN1 P39748 2/20 0.39
ALOX5AP P20292 1/20 0.39
IRAK1 P51617 1/20 0.39
HPGDS O60760 1/20 0.39
NAMPT P43490 1/20 0.39
KEAP1 Q14145 1/20 0.38
NFE2L2 Q16236 1/20 0.38
GAA P10253 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5870789 0.91 CYP2C9 (0.46) CYP2C9GPR119BACE1ACKR3CTSD
SCHEMBL5870788 0.88 ACKR3 (0.50) BACE1ACKR3CTSDKDM1AFEN1
SCHEMBL5870776 0.88 ACKR3 (0.50) BACE1ACKR3CTSDKDM1AFEN1
SCHEMBL5871030 0.88 ACKR3 (0.50) BACE1ACKR3CTSDKDM1AFEN1
SCHEMBL5870884 0.84 CYP2C9 (0.43) CYP2C9GPR119BACE1ACKR3CTSD
SCHEMBL5870963 0.79 KAT7 (0.46) GPR119BACE1ACKR3CTSDKDM1A
SCHEMBL5870830 0.79 ACHE (0.56) CYP2C9ACKR3KDM1AFEN1
SCHEMBL5870690 0.79 ACKR3 (0.49) BACE1ACKR3CTSDKDM1AFEN1
SCHEMBL5870694 0.79 PTPRB (0.52) BACE1ACKR3CTSDKDM1AFEN1
SCHEMBL5870688 0.78 ACKR3 (0.54) CYP2C9GPR119ACKR3KDM1AGLS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7129228-B2 Heterocyclic analgesic compounds and methods of use thereof SEPRACOR INC. (US) 2006-10-31 US disclosed
US-20040209846-A1 Heterocyclic analgesic compounds and methods of use thereof CUNY GREGORY D (US) 2004-10-21 US disclosed
US-6677332-B1 AMIDE-SUBSTITUTED PIPERIDINE OR AZEPINE DERIVATIVES TO TREAT DRUG ABUSE AND TINNITUS SEPRACOR, INC. 2004-01-13 US disclosed
US-6645980-B1 Ligands for biological receptors such as opiate receptors or G-protein coupled receptors used for treating pain, drug dependence or tinnitus in mammals SEPRACOR INC. 2003-11-11 US disclosed
US-6635661-B2 Piperidinyl amide compounds SEPRACOR INC. 2003-10-21 US disclosed
US-20020016337-A1 Heterocyclic analgesic compounds and methods of use thereof SEPRACOR INC. 2002-02-07 US disclosed
WO-2001092226-A1 HETEROCYCLIC ANALGESIC COMPOUNDS AND METHOD OF USE THEREOF SEPRACOR, INC. (US) 2001-12-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040209846-A1 Heterocyclic analgesic compounds and methods of use thereof OPRL1, TRPV1, OPRK1 CYP2C9 794/4885GPR119 697/4885BACE1 3597/4885
US-20020016337-A1 Heterocyclic analgesic compounds and methods of use thereof OPRL1, TRPV1, OPRK1 CYP2C9 794/4885GPR119 697/4885BACE1 3597/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.